Global Virus Like Particles Market & Clinical Trial Insight 2023
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
Vaccination is considered the most cost effective way to control the pathogens and prevent the diseases both in humans and veterinary field. The vaccines based on virus like particles represent one of the most appealing and cost effective approaches due to the intrinsic immunogenic properties as well as high safety profile. The virus like particles also offers several other advantages against the emerging viruses and these are virus like particles are not live viruses and thus manufacturing process offers a safer environment for the operators.
The modern approach for the development of vaccines is focused on the identification of the molecular entities from different organisms as candidates which can mimic the role of viruses. This approach is certainly safer and produces lesser or no side effects after the vaccination process. Virus-like particles are one of such candidates which have shown most promising results and are currently involved in treating a wide range of diseases.
Virus-like particles are composed of the characteristic building proteins of a virus which mimic the properties of the infectious viruses but lack the viral genome. Therefore, Virus like particles became an extremely impressive and promising vaccine candidates due to the presence of virus like but yet non-infective properties in them. Thus, the viruses like particle based vaccines are potentially safer candidates for developing vaccines. Furthermore, Virus like particles are able to induce both innate and adaptive immune responses in humans. Most of the virus like particle based vaccines are derived from the bacteria E.coli as the bacteria E. coli has many advantages, such as inexpensive culturing, high expression levels and easy large scale production. All these advantages of the bacteria will consequentially serve to the development of more cost effective vaccines.
“Global Virus Like Particles Market & Clinical Trial Insight 2023” report highlights:
The major pharmaceutical companies have recognized the promising future of the virus like particle vaccines and are widely supporting the manufacturing and production of such vaccines. Major market players include some of the large scale pharmaceutical companies like GlaxoSmithKline's and Merck. The development of the cost effective vaccines are hugely supported by the governmental authorities as well as the academia and pharmaceutical companies.
The future of the virus like particle based vaccines is bright owing to the presence of multiple favorable factors and lesser challenges. The low cost and high efficiency combination will contribute as a robust of the virus like particle vaccines market. Such kind of vaccines will be easily accessible to the consumers due to the expanding market size. The future is even more optimistic in the developing countries where low price will be a favorable parameter for increased customers and demands. Overall the future of the virus like particle based vaccine is very bright and may result in replacing the whole human vaccine market by collecting high revenues for the pharmaceutical industry.
Vaccination is considered the most cost effective way to control the pathogens and prevent the diseases both in humans and veterinary field. The vaccines based on virus like particles represent one of the most appealing and cost effective approaches due to the intrinsic immunogenic properties as well as high safety profile. The virus like particles also offers several other advantages against the emerging viruses and these are virus like particles are not live viruses and thus manufacturing process offers a safer environment for the operators.
The modern approach for the development of vaccines is focused on the identification of the molecular entities from different organisms as candidates which can mimic the role of viruses. This approach is certainly safer and produces lesser or no side effects after the vaccination process. Virus-like particles are one of such candidates which have shown most promising results and are currently involved in treating a wide range of diseases.
Virus-like particles are composed of the characteristic building proteins of a virus which mimic the properties of the infectious viruses but lack the viral genome. Therefore, Virus like particles became an extremely impressive and promising vaccine candidates due to the presence of virus like but yet non-infective properties in them. Thus, the viruses like particle based vaccines are potentially safer candidates for developing vaccines. Furthermore, Virus like particles are able to induce both innate and adaptive immune responses in humans. Most of the virus like particle based vaccines are derived from the bacteria E.coli as the bacteria E. coli has many advantages, such as inexpensive culturing, high expression levels and easy large scale production. All these advantages of the bacteria will consequentially serve to the development of more cost effective vaccines.
“Global Virus Like Particles Market & Clinical Trial Insight 2023” report highlights:
- Advances in Virus like Particles as a Vaccination
- Production Process of Virus like Particle based Vaccines
- Market Analysis of Virus like Particles Vaccines
- Global Virus Like Particle Vaccines Clinical Pipeline Insight: 60 Vaccines
- Marketed Virus Like Particle Vaccines Clinical Insight: 5 Vaccines
- Future Perspective of Virus like Particles Vaccines
The major pharmaceutical companies have recognized the promising future of the virus like particle vaccines and are widely supporting the manufacturing and production of such vaccines. Major market players include some of the large scale pharmaceutical companies like GlaxoSmithKline's and Merck. The development of the cost effective vaccines are hugely supported by the governmental authorities as well as the academia and pharmaceutical companies.
The future of the virus like particle based vaccines is bright owing to the presence of multiple favorable factors and lesser challenges. The low cost and high efficiency combination will contribute as a robust of the virus like particle vaccines market. Such kind of vaccines will be easily accessible to the consumers due to the expanding market size. The future is even more optimistic in the developing countries where low price will be a favorable parameter for increased customers and demands. Overall the future of the virus like particle based vaccine is very bright and may result in replacing the whole human vaccine market by collecting high revenues for the pharmaceutical industry.
1. VIRUS LIKE PARTICLES – NEW GENERATION OF VACCINES
1.1 Introduction
1.2 Requirements for Virus like Particles Assembly
2. VIRUS CANDIDATES FOR DEVELOPMENT OF VIRUS LIKE PARTICLE VACCINES
2.1 Animal Virus-like Particles as Vaccine Immunogens
2.2 Plant Virus based Virus like Particles
3. CURRENT ADVANCES IN VIRUS LIKE PARTICLES AS A VACCINATION APPROACH AGAINST INFECTIOUS DISEASES
3.1 HIV-1 Virus like Particles
3.2 Hepatitis C Virus
3.3 Malaria
3.4 Newcastle Disease
3.5 Filoviruses
3.6 Norovirus
4. PRODUCTION PROCESS OF VIRUS LIKE PARTICLE BASED VACCINES
4.1 Expression Systems
4.2 Downstream Processing of Virus like Particle Based Vaccines
5. MARKET ANALYSIS OF VIRUS LIKE PARTICLES VACCINES
5.1 Introduction
5.2 Market of Virus like Particle Vaccines
6. GLOBAL VIRUS LIKE PARTICLE VACCINES CLINICAL PIPELINE OVERVIEW
7. GLOBAL VIRUS LIKE PARTICLE VACCINES MARKET DYNAMICS
7.1 Favorable Parameters
7.2 Commercialization Challenges
8. FUTURE PERSPECTIVE OF VIRUS LIKE PARTICLES VACCINES
9. GLOBAL VIRUS LIKE PARTICLE VACCINES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
9.1 Research
9.2 Preclinical
9.3 Phase-I
9.4 Phase-I/II
9.5 Phase-II
9.6 Phase-II/III
9.7 Phase-III
10. MARKETED VIRUS LIKE PARTICLE VACCINES CLINICAL INSIGHT
10.1 Human papillomavirus vaccine recombinant quadrivalent (Gardasil & Silgard)
10.2 Human papillomavirus vaccine recombinant bivalent (Cervarix)
10.3 Human Papillomavirus Vaccine Recombinant Nonavalent (GARDASIL9)
10.4 Influenza Virus Vaccine Trivalent (CadiFlu-S)
10.5 Influenza A Virus H1N1 Vaccine (CadiFlu)
11. COMPETITIVE LANDSCAPE
11.1 Agilvax
11.2 Allergy Therapeutics
11.3 ANGANY Genetics
11.4 CPL Biologicals
11.5 Cytos Biotechnology
11.6 GeoVax Labs
11.7 GlaxoSmithKline
11.8 Medicago
11.9 MedImmune
11.10 Merck
11.11 Novavax
11.12 Serum Institute of India
11.13 Takeda
11.14 TechnoVax
11.15 Xiamen Innovax Biotech
1.1 Introduction
1.2 Requirements for Virus like Particles Assembly
2. VIRUS CANDIDATES FOR DEVELOPMENT OF VIRUS LIKE PARTICLE VACCINES
2.1 Animal Virus-like Particles as Vaccine Immunogens
2.2 Plant Virus based Virus like Particles
3. CURRENT ADVANCES IN VIRUS LIKE PARTICLES AS A VACCINATION APPROACH AGAINST INFECTIOUS DISEASES
3.1 HIV-1 Virus like Particles
3.2 Hepatitis C Virus
3.3 Malaria
3.4 Newcastle Disease
3.5 Filoviruses
3.6 Norovirus
4. PRODUCTION PROCESS OF VIRUS LIKE PARTICLE BASED VACCINES
4.1 Expression Systems
4.2 Downstream Processing of Virus like Particle Based Vaccines
5. MARKET ANALYSIS OF VIRUS LIKE PARTICLES VACCINES
5.1 Introduction
5.2 Market of Virus like Particle Vaccines
6. GLOBAL VIRUS LIKE PARTICLE VACCINES CLINICAL PIPELINE OVERVIEW
7. GLOBAL VIRUS LIKE PARTICLE VACCINES MARKET DYNAMICS
7.1 Favorable Parameters
7.2 Commercialization Challenges
8. FUTURE PERSPECTIVE OF VIRUS LIKE PARTICLES VACCINES
9. GLOBAL VIRUS LIKE PARTICLE VACCINES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
9.1 Research
9.2 Preclinical
9.3 Phase-I
9.4 Phase-I/II
9.5 Phase-II
9.6 Phase-II/III
9.7 Phase-III
10. MARKETED VIRUS LIKE PARTICLE VACCINES CLINICAL INSIGHT
10.1 Human papillomavirus vaccine recombinant quadrivalent (Gardasil & Silgard)
10.2 Human papillomavirus vaccine recombinant bivalent (Cervarix)
10.3 Human Papillomavirus Vaccine Recombinant Nonavalent (GARDASIL9)
10.4 Influenza Virus Vaccine Trivalent (CadiFlu-S)
10.5 Influenza A Virus H1N1 Vaccine (CadiFlu)
11. COMPETITIVE LANDSCAPE
11.1 Agilvax
11.2 Allergy Therapeutics
11.3 ANGANY Genetics
11.4 CPL Biologicals
11.5 Cytos Biotechnology
11.6 GeoVax Labs
11.7 GlaxoSmithKline
11.8 Medicago
11.9 MedImmune
11.10 Merck
11.11 Novavax
11.12 Serum Institute of India
11.13 Takeda
11.14 TechnoVax
11.15 Xiamen Innovax Biotech
LIST OF FIGURES
Figure 1-1: Non-Enveloped Virus like Particle Production through Pathogen Component & Fusion to a Vaccine Target Antigen
Figure 1-2: Diagram of Enveloped Virus like Particle Production
Figure 1-3: Requirements for the Assembly of Virus like Particles
Figure 2-1: Types of Plant Virus for Virus like Particles Development
Figure 3-1: Modification of HIV-1 Envelope Trimers for Virus like Particle Vaccine
Figure 3-2: Virus like Particle Vaccine Strategy against Hepatitis C virus
Figure 3-3: New Castle Virus for Virus like Particle Vaccine Development
Figure 3-4: Production of Ebola Virus like Particles from Plasmids
Figure 4-1: Downstream Process Strategy for Virus like Particle Purification
Figure 5-1: Global - Market Growth Potential of Vaccine Industry (US$, Billion), 2017-2023
Figure 6-1: Global – Virus Like Particle Vaccines Pipeline by Phase (%), 2017 till 2023
Figure 6 2: Global –Virus Like Particle Vaccines Pipeline by Phase (Number), 2017 till 2023
Figure 6-3: Global – Virus Like Particle Vaccines Pipeline by Phase (%),2017 till 2023
Figure 6-4: Global – Virus Like Particle Vaccines Pipeline by Phase (Number), 2017 till 2023
Figure 7-1: Favorable Market Parameters for Vaccine Development
Figure 7-2: Challenges to the Market Growth of Vaccines
Figure 8-1: Future Scientific Innovations and Challenges for Vaccine Development
Figure 1-1: Non-Enveloped Virus like Particle Production through Pathogen Component & Fusion to a Vaccine Target Antigen
Figure 1-2: Diagram of Enveloped Virus like Particle Production
Figure 1-3: Requirements for the Assembly of Virus like Particles
Figure 2-1: Types of Plant Virus for Virus like Particles Development
Figure 3-1: Modification of HIV-1 Envelope Trimers for Virus like Particle Vaccine
Figure 3-2: Virus like Particle Vaccine Strategy against Hepatitis C virus
Figure 3-3: New Castle Virus for Virus like Particle Vaccine Development
Figure 3-4: Production of Ebola Virus like Particles from Plasmids
Figure 4-1: Downstream Process Strategy for Virus like Particle Purification
Figure 5-1: Global - Market Growth Potential of Vaccine Industry (US$, Billion), 2017-2023
Figure 6-1: Global – Virus Like Particle Vaccines Pipeline by Phase (%), 2017 till 2023
Figure 6 2: Global –Virus Like Particle Vaccines Pipeline by Phase (Number), 2017 till 2023
Figure 6-3: Global – Virus Like Particle Vaccines Pipeline by Phase (%),2017 till 2023
Figure 6-4: Global – Virus Like Particle Vaccines Pipeline by Phase (Number), 2017 till 2023
Figure 7-1: Favorable Market Parameters for Vaccine Development
Figure 7-2: Challenges to the Market Growth of Vaccines
Figure 8-1: Future Scientific Innovations and Challenges for Vaccine Development
LIST OF TABLES
Table 3-1: Development Status of Virus like Particle Vaccine Candidates
Table 4-1: Properties of Various Expression Systems for Production of Virus like Particle
COMPANIES
Agilvax,
Allergy Therapeutics,
ANGANY Genetics,
CPL Biologicals,
Cytos Biotechnology,
GeoVax Labs,
GlaxoSmithKline,
Medicago,
MedImmune,
Merck,
Novavax,
Serum Institute of India,
Takeda,
TechnoVax,
Xiamen Innovax Biotech
Table 3-1: Development Status of Virus like Particle Vaccine Candidates
Table 4-1: Properties of Various Expression Systems for Production of Virus like Particle
COMPANIES
Agilvax,
Allergy Therapeutics,
ANGANY Genetics,
CPL Biologicals,
Cytos Biotechnology,
GeoVax Labs,
GlaxoSmithKline,
Medicago,
MedImmune,
Merck,
Novavax,
Serum Institute of India,
Takeda,
TechnoVax,
Xiamen Innovax Biotech
